Press Releases Investor Overview Press Releases Events and Presentations Upcoming Events Past Events Presentations Analyst Coverage SEC Filings Stock Information Stock Quote & Chart Historical Price Lookup Investment Calculator Corporate Governance Governance Overview Management Board of Directors Committee Composition Information Request Investor Overview Press Releases Events and Presentations Upcoming Events Past Events Presentations Analyst Coverage SEC Filings Stock Information Stock Quote & Chart Historical Price Lookup Investment Calculator Corporate Governance Governance Overview Management Board of Directors Committee Composition Information Request Year None20242023202220212020 December 11, 2024 Protara Announces Closing of $100 Million Public Offering December 9, 2024 Protara Announces Pricing of $100 Million Public Offering December 9, 2024 Protara Announces Proposed Public Offering December 5, 2024 Protara Announces Positive Results from the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC December 3, 2024 Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC on Thursday, December 5, 2024 November 15, 2024 Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the 25th Annual Meeting of the Society of Urologic Oncology November 12, 2024 Protara Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update November 6, 2024 Protara Therapeutics to Present at the Guggenheim Inaugural Healthcare Innovation Conference October 21, 2024 Protara Therapeutics Granted FDA Fast Track Designation for Intravenous Choline Chloride for Patients Receiving Parenteral Support September 9, 2024 Protara Therapeutics Announces Completion of First Cohort in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations September 9, 2024 Protara Therapeutics Announces Results from THRIVE-1, a Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Support September 3, 2024 Protara Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Next page › Last page » Displaying 1 - 12 of 92 Print Print Email Alerts Email Alerts RSS Feeds RSS Feeds Email Page Email Page
Year None20242023202220212020 December 11, 2024 Protara Announces Closing of $100 Million Public Offering December 9, 2024 Protara Announces Pricing of $100 Million Public Offering December 9, 2024 Protara Announces Proposed Public Offering December 5, 2024 Protara Announces Positive Results from the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC December 3, 2024 Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC on Thursday, December 5, 2024 November 15, 2024 Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the 25th Annual Meeting of the Society of Urologic Oncology November 12, 2024 Protara Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update November 6, 2024 Protara Therapeutics to Present at the Guggenheim Inaugural Healthcare Innovation Conference October 21, 2024 Protara Therapeutics Granted FDA Fast Track Designation for Intravenous Choline Chloride for Patients Receiving Parenteral Support September 9, 2024 Protara Therapeutics Announces Completion of First Cohort in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations September 9, 2024 Protara Therapeutics Announces Results from THRIVE-1, a Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Support September 3, 2024 Protara Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Next page › Last page » Displaying 1 - 12 of 92
December 5, 2024 Protara Announces Positive Results from the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC
December 3, 2024 Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC on Thursday, December 5, 2024
November 15, 2024 Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the 25th Annual Meeting of the Society of Urologic Oncology
November 12, 2024 Protara Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update
November 6, 2024 Protara Therapeutics to Present at the Guggenheim Inaugural Healthcare Innovation Conference
October 21, 2024 Protara Therapeutics Granted FDA Fast Track Designation for Intravenous Choline Chloride for Patients Receiving Parenteral Support
September 9, 2024 Protara Therapeutics Announces Completion of First Cohort in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations
September 9, 2024 Protara Therapeutics Announces Results from THRIVE-1, a Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Support
September 3, 2024 Protara Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
